Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer

被引:115
|
作者
Yi, Joo Mi [1 ,9 ]
Dhir, Mashaal [2 ]
Van Neste, Leander [4 ,5 ]
Downing, Stephanie R. [2 ]
Jeschke, Jana [2 ]
Gloeckner, Sabine C. [2 ]
Calmon, Marilia de Freitas [2 ]
Hooker, Craig M. [1 ]
Funes, Juan M. [4 ,6 ]
Boshoff, Chris [4 ,6 ]
Smits, Kim M. [7 ]
van Engeland, Manon [7 ]
Weijenberg, Matty P. [7 ]
Iacobuzio-Donahue, Christine A. [3 ]
Herman, James G. [1 ]
Schuebel, Kornel E. [8 ]
Baylin, Stephen B. [1 ]
Ahuja, Nita [1 ,2 ]
机构
[1] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Dept Surg, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA
[4] Univ Ghent, Dept Mol Biotechnol, Fac Biosci Engn, B-9000 Ghent, Belgium
[5] MDxHealth, Ghent, Belgium
[6] UCL, Canc Res UK Viral Oncol Grp, London, England
[7] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Pathol, Maastricht, Netherlands
[8] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA
[9] Dongnam Inst Radiol & Res Med Sci DIRAMS, Res Ctr, Pusan, South Korea
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; DNA METHYLATION MARKERS; PROMOTER HYPERMETHYLATION; COLORECTAL CARCINOMAS; TUMOR PROGRESSION; TISSUE INHIBITOR; GENE-EXPRESSION; HUMAN BREAST; STEM-CELLS; INACTIVATION;
D O I
10.1158/1078-0432.CCR-10-2509
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The importance of genetic and epigenetic alterations maybe in their aggregate role in altering core pathways in tumorigenesis. Experimental Design: Merging genome-wide genomic and epigenomic alterations, we identify key genes and pathways altered in colorectal cancers (CRC). DNA methylation analysis was tested for predicting survival in CRC patients using Cox proportional hazard model. Results: We identified 29 low frequency-mutated genes that are also inactivated by epigenetic mechanisms in CRC. Pathway analysis showed the extracellular matrix (ECM) remodeling pathway is silenced in CRC. Six ECM pathway genes were tested for their prognostic potential in large CRC cohorts (n = 777). DNA methylation of IGFBP3 and EVL predicted for poor survival (IGFBP3: HR = 2.58, 95% CI: 1.37-4.87, P = 0.004; EVL: HR = 2.48, 95% CI: 1.07-5.74, P = 0.034) and simultaneous methylation of multiple genes predicted significantly worse survival (HR = 8.61, 95% CI: 2.16-34.36, P < 0.001 for methylation of IGFBP3, EVL, CD109, and FLNC). DNA methylation of IGFBP3 and EVL was validated as a prognostic marker in an independent contemporary-matched cohort (IGFBP3 HR = 2.06, 95% CI: 1.04-4.09, P - 0.038; EVL HR - 2.23, 95% CI: 1.00-5.0, P - 0.05) and EVL DNA methylation remained significant in a secondary historical validation cohort (HR = 1.41, 95% CI: 1.05-1.89, P = 0.022). Moreover, DNA methylation of selected ECM genes helps to stratify the high-risk stage 2 colon cancers patients who would benefit from adjuvant chemotherapy (HR: 5.85, 95% CI: 2.03-16.83, P = 0.001 for simultaneous methylation of IGFBP3, EVL, and CD109). Conclusions: CRC that have silenced genes in ECM pathway components show worse survival suggesting that our finding provides novel prognostic biomarkers for CRC and reflects the high importance of integrative analyses linking genetic and epigenetic abnormalities with pathway disruption in cancer. Clin Cancer Res; 17(6); 1535-45. (C) 2011 AACR.
引用
收藏
页码:1535 / 1545
页数:11
相关论文
共 50 条
  • [1] Genomic analysis identifies novel prognostic signature for breast cancer
    Wilson, Hannah
    BIOMARKERS IN MEDICINE, 2013, 7 (03) : 396 - 396
  • [3] Epigenomic Enhancer Profiling Defines a Signature of Colon Cancer
    Akhtar-Zaidi, Batool
    Lari, Richard Cowper-Sal
    Corradin, Olivia
    Saiakhova, Alina
    Bartels, Cynthia F.
    Balasubramanian, Dheepa
    Myeroff, Lois
    Lutterbaugh, James
    Jarrar, Awad
    Kalady, Matthew F.
    Willis, Joseph
    Moore, Jason H.
    Tesar, Paul J.
    Laframboise, Thomas
    Markowitz, Sanford
    Lupien, Mathieu
    Scacheri, Peter C.
    SCIENCE, 2012, 336 (6082) : 736 - 739
  • [4] Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer
    Maak, Matthias
    Simon, Iris
    Nitsche, Ulrich
    Roepman, Paul
    Snel, Mireille
    Glas, Annuska M.
    Schuster, Tibor
    Keller, Gisela
    Zeestraten, Eliane
    Goossens, Ines
    Janssen, Klaus-Peter
    Friess, Helmut
    Rosenberg, Robert
    ANNALS OF SURGERY, 2013, 257 (06) : 1053 - 1058
  • [5] Distinct genomic and epigenomic features demarcate hypomethylated blocks in colon cancer
    Sharmin, Mahfuza
    Bravo, Hector Corrada
    Hannenhalli, Sridhar
    BMC CANCER, 2016, 16
  • [6] Distinct genomic and epigenomic features demarcate hypomethylated blocks in colon cancer
    Mahfuza Sharmin
    Héctor Corrada Bravo
    Sridhar Hannenhalli
    BMC Cancer, 16
  • [7] Epigenomic colon cancer kit
    Mullard, Asher
    Nature Biotechnology, 2009, 27 (12) : 1066 - 1066
  • [8] Prostate cancer genomic signature offers prognostic value
    Troutman, Sarah M.
    Price, Douglas K.
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2010, 10 (11) : 1079 - 1080
  • [9] Integrated analysis of genomic and epigenomic regulation of transcriptome identifies molecular subtypes of liver cancer
    Woo, H. G.
    Choi, J-H
    Cho, E. J.
    Lee, J-H
    Yu, S. J.
    Yoon, J-H
    Lee, K-W
    Suh, K-S
    Kim, Y. J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S639 - S640
  • [10] Genomic and Epigenomic Alterations in Cancer
    Chakravarthi, Balabhadrapatruni V. S. K.
    Nepal, Saroj
    Varambally, Sooryanarayana
    AMERICAN JOURNAL OF PATHOLOGY, 2016, 186 (07): : 1724 - 1735